Connect with us
Almirall collaborates with Microsoft to enhance dermatological innovation through AI techniques, improving data analysis, developing synthesizable molecules, and optimizing data management processes in drug discovery. The...
In 2024, Novo Nordisk expects its sales to increase between 18% and 26% at constant exchange rates, while it anticipates operating profit growth at constant exchange...
The approval of the treatment is based on two pivotal phase III clinical trials: M15-741 and M-15-736. Primary endpoint results from the first trial showed that...
The Spanish health AI sector will go from moving €130 million in 2022 to generating €2.5 billion in 2030. Companies such as Almirall, Grifols or Faes...
There are also signs to anticipate the entry into a consolidation phase of the digital health business. The merger and acquisition (M&A) of companies in this...
In December 2023, the company reached an agreement to acquire the entire share capital of the Chinese start-up Gracell Biotechnologies for a price that could reach...
The path laid out by general pharmaceutical legislation, according to the Asebio study's conclusions, makes it less likely to achieve objectives related to, for example, rare...
With the transaction, Sanofi will assume and repay Inhibrx's outstanding third-party debt and will finance New Inhibrx with $200 million in cash (€183 million) and retain...
In 2021, Teva's Spanish subsidiary had a turnover of around 412 million euros in a global context of slowing turnover, which in 2022 fell by 6%....
The second Spanish biotech company most endorsed by investors last year was the Valencian Arthex Biotech, protagonist of a round of 42 million. Specialized in therapies...
 |
|
 |  |
 |
|